Latest advancements in TB science in spotlight

Important game-changing scientific advancements in preventing and treating TB (TB or tuberculosis, is among the deadliest of infectious diseases globally), were in spotlight at the recently concluded International Conference on Retroviruses and other Opportunistic Infections (CROI 2022).

Far from the promise of endgame, tobacco epidemic continues...

Tobacco industry-propelled epidemic of tobacco-caused diseases and untimely deaths continue to plague human development. Despite significant progress on tobacco control, endgame of tobacco - which is a human rights and social justice imperative - is not yet in sight. The recently released 7th edition of Tobacco Atlas shows that while global smoking prevalence in adults has declined from 22.7% in 2007 to 19.6% in 2019, we still have 1.3 billion tobacco users in the world. The progress on the endgame of tobacco is also threatened by the growing tobacco smoking rates among children aged 13 to 15 years in many countries, and by tobacco industry tactics targeting poorer countries with weak regulatory environments and pushing so-called 'novel' products in previously untapped markets.

Drug-resistant TB: Are we converting scientific breakthroughs into public health gains?

[listen to The Dose Podcast that premiered on 2022 World TB Day] [हिंदी] Undoubtedly, among the most important scientific breakthroughs for the diagnosis and treatment of drug-resistant tuberculosis (TB) have happened in the past few years. But are we able to convert the scientific breakthroughs into public health gains quickly enough - by diagnosing every person with drug-resistant TB, and treating them with safe and effective medicines?